Transcriptional reprogramming in SMA mouse hearts reveals signatures of early heart failure and dysregulated calcium signaling
- PMID: 40287831
- PMCID: PMC12199365
- DOI: 10.1093/hmg/ddaf060
Transcriptional reprogramming in SMA mouse hearts reveals signatures of early heart failure and dysregulated calcium signaling
Abstract
Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease that leads to loss of motor neurons in the anterior horn of the spinal cord with consequent muscle atrophy. SMA results from the functional deletions of the SMN1 gene, resulting in insufficient production of the survival motor neuron (SMN) protein. It is not known why lower motor neurons are particularly sensitive to the loss of SMN function, but it is increasingly apparent that extraneuronal tissues, such as cardiac and skeletal muscle, are also affected by SMN deficiency. We have previously shown that SMN deficiency in a mouse model of spinal muscular atrophy (SMNΔ7) impairs cardiomyocyte contraction and Ca2+ handling. In this study, we performed a comparative total mRNA sequencing analysis of whole hearts isolated at an early (P5) or late (P10) stage of the disease process to investigate the mechanisms contributing to cardiac pathology in SMA. The results demonstrate transcriptional signatures consistent with heart failure, dysregulation of Ca2+ signaling, and hypoxia induced changes occurring as early as P5 and persisting through P10. Similar transcriptomic changes in skeletal muscle tissue indicate that there are likely common, cell autonomous molecular mechanisms resulting in both cardiac and skeletal muscle due to SMN deficiency. The identification of these common themes suggests a link underlying the mechanism of neuronal and non-neuronal deficits in SMA.
Keywords: calcium; neurodegenerative disease; spinal muscular atrophy; transcriptomics.
Published by Oxford University Press 2025.
Similar articles
-
Cardiac pathology in spinal muscular atrophy: a systematic review.Orphanet J Rare Dis. 2017 Apr 11;12(1):67. doi: 10.1186/s13023-017-0613-5. Orphanet J Rare Dis. 2017. PMID: 28399889 Free PMC article.
-
Administration of adipose-derived stem cells extracellular vesicles in a murine model of spinal muscular atrophy: effects of a new potential therapeutic strategy.Stem Cell Res Ther. 2024 Apr 1;15(1):94. doi: 10.1186/s13287-024-03693-5. Stem Cell Res Ther. 2024. PMID: 38561840 Free PMC article.
-
The effect of coadministration of D156844 and AR42 (REC-2282) on the survival and motor phenotype of mice with spinal muscular atrophy.Sci Rep. 2025 Aug 7;15(1):28866. doi: 10.1038/s41598-025-12194-1. Sci Rep. 2025. PMID: 40775246 Free PMC article.
-
Dysregulated balance of D- and L-amino acids modulating glutamatergic neurotransmission in severe spinal muscular atrophy.Neurobiol Dis. 2025 Apr;207:106849. doi: 10.1016/j.nbd.2025.106849. Epub 2025 Feb 24. Neurobiol Dis. 2025. PMID: 40010612 Free PMC article.
-
Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence.Int J Mol Sci. 2025 Jun 18;26(12):5858. doi: 10.3390/ijms26125858. Int J Mol Sci. 2025. PMID: 40565321 Free PMC article. Review.
References
-
- Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000;15:228–237. - PubMed
-
- Chang WF, Xu J, Chang CC. et al. SMN is required for the maintenance of embryonic stem cells and neuronal differentiation in mice. Brain Struct Funct 2015;220:1539–1553. - PubMed
-
- Mendell JR, Al-Zaidy S, Shell R. et al. Single-Dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017;377:1713–1722. - PubMed
-
- Finkel RS, Mercuri E, Darras BT. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723–1732. - PubMed
-
- Ratni H, Ebeling M, Baird J. et al. Discovery of Risdiplam, a selective survival of motor Neuron-2 ( SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem 2018;61:6501–6517. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous